Fixed dose combination products for chronic diseases, AIDS, TB and malaria: benefits and regulatory challenges
- At: 2006 FIP Congress in Salvadore (Brazil)
- Type: Presentation
- By: WANING, Brenda (Boston University, International Health, Cambridge, United States of America)
There has been much discussion on the role of fixed-dose combination (FDC) medicines for the treatment of several conditions, specifically: cardiovascular disease, hypertension, diabetes, HIV/AIDS, tuberculosis, and malaria. National and international organizations including WHO, UNAIDS, US DHHS, and others have made formal statements in support.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.